Company intelligence / Profile preview

Beijing Kangming Hanghui Biotechnology

Zhejiang Sheng, China

Ownership: Private
Development stage: Other

Overview

Beijing Kangming Hanghui Biotechnology is a private Chinese biotech company focused on developing small molecule drugs for oncology. Its lead asset, KMHH-03, is an HSP90B1 inhibitor currently in a Phase 1 clinical trial for advanced breast cancer. The ongoing study evaluates safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy to inform future development.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

KMHH-03

Beyond the preview

Go deeper on Beijing Kangming Hanghui Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Kangming Hanghui Biotechnology.